BioLineRx is trading at $2.57 (-6.81%) in after-hours trading after second-quarter revenue missed expectations and APHEXDA royalty income remained weak.
- The August 31, 2026 report showed $0.3 million in revenue versus $0.5 million expected.
- Management highlighted continued GLIX1 clinical spending; the recent $3.75 million offering and attached warrants may weigh on sentiment through dilution concerns.
- Broader risk-off markets added pressure, with the Nasdaq down 1.15%.